Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00069017 · ClinicalTrials.gov registry record · Phase 2
Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate
A Phase 2 study of Rheumatoid Arthritis, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT00069017 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by MedImmune. The registered enrollment target is 300 participants, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT00069017, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
To compare, as a preliminary analysis, the effects of MEDI-522 versus placebo at 6 months on disease activity (ACR20) and progression of structural joint damage.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL MEDI-522
Study Locations (20)
Florida
- Arthritis and Rheumatic Disease Specialty - Aventura
- Centre for Rheumatology, Immunology & Arthritis - Fort Lauderdale
- Ocala Rheumatology Research Center - Ocala
- Sarasota Arthritis Research Center - Sarasota
Arizona
- Sun Valley Arthritis Center - Glendale
- Arizona Research & Education - Phoenix
- University of Arizona - Tucson
California
- Thornton Hospital - La Jolla
- Boling Clinical Trials - Rancho Cucamonga
- Pacific Arthritis Center Medical Group - Santa Maria
Missouri
- RIMA - St Louis
- Arthritis Consultants, Inc. - St Louis
Oklahoma
- Health Research Institute - Oklahoma City
- Lynn Health Science Institute - Oklahoma City
Alabama
- The University of Alabama at Birmingham - Birmingham
Arkansas
- Fayetteville Diagnostic Clinic, Ltd. - Fayetteville
Georgia
- Sanford S. Hartman - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2003-09 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00069017
The ClinicalTrials.gov registry entry for NCT00069017 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (94% lower). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00069017 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT00069017 about?
NCT00069017 is a clinical study titled "Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate". To compare, as a preliminary analysis, the effects of MEDI-522 versus placebo at 6 months on disease activity (ACR20) and progression of structural joint damage.
What is the current status of trial NCT00069017?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2003-09. Estimated completion is 2006-04.
What conditions does trial NCT00069017 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT00069017?
The interventions under investigation include: Placebo (OTHER), MEDI-522 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00069017?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00069017 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of SPY072 in Rheumatic Disease
RECRUITING · Phase 2
-
Dynamic Treatment Regiments for Glucocorticoid Tapering
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
RECRUITING · Phase 2
-
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.